Inflammation has been associated with the two classic lesions in the Alzheimer's (AD) brain, amyloid deposits and neurofibrillary tangles. Recent data suggest that Triflusal, a compound with potent antiinflammatory effects in the central nervous system in vivo, might delay the conversion from amnestic mild cognitive impairment to a fully established clinical picture of dementia. In the present study, we investigated the effect of Triflusal on brain Aβ accumulation, neuroinflammation, axonal curvature and cognition in an AD transgenic mouse model (Tg2576). Triflusal treatment did not alter the total brain Aβ accumulation but significantly reduced dense-cored plaque load and associated glial cell proliferation, proinflammatory cytokine levels and abnormal axonal curvature, and rescued cognitive deficits in Tg2576 mice. Behavioral benefit was found to involve increased expression of c-fos and BDNF, two of the genes regulated by CREB, as part of the signal transduction cascade underlying the molecular basis of long-term potentiation. These results add preclinical evidence of a potentially beneficial effect of Triflusal in AD.
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Introduction
Neuropathological and epidemiological data suggest that inflammation plays an important role in Alzheimer's disease (AD) (WyssCoray, 2006). Abundant activated microglia and astrocytes, and release of proinflammatory mediators have been invariantly identified in AD brains in association with the classic extracellular deposits of amyloid called senile plaques (SP), in particular with dense-core or fibrillar Aβ-containing plaques, and are believed to contribute to neurotoxicity (Akiyama et al., 2000; Koenigsknecht and Landreth, 2004) . In addition, multiple epidemiological investigations point to a risk reduction in long-term users of non-steroidal anti-inflammatory drugs (NSAIDs) (McGeer and McGeer, 1996; Wyss-Coray, 2006) . The biological mechanism underlying this protection is not completely understood. Even though the main activity of NSAIDs is to inhibit cyclooxygenase (COX) activity, other mechanisms of action have been proposed for activity of certain NSAIDs such inhibition of amyloid-β formation, PPAR-gamma agonism and NFkappaB negative regulation or stimulation of neurotrophin synthesis, that could be potentially beneficial in AD (reviewed in Imbimbo, 2009 ). Multiple studies have tested the effects of traditional NSAIDs on transgenic mouse models of AD. Consistent in most of these studies there is a reduction of activated microglia in many cases accompanied by a decrease in Aβ load (reviewed in McGeer and McGeer, 2007) . However, placebocontrolled clinical trials with NSAIDs in AD patients have produced negative results so far (reviewed in McGeer and McGeer, 2007) . A trial with rofecoxib in individuals with mild cognitive impairment (MCI) was also negative (Thal, 2005) . The primary prevention study with naproxen and celecoxib (ADAPT) in elderly subjects at high risk of dementia was terminated early because of cardiovascular risks associated with both these agents, and meaningful data on the study's primary outcome (prevention of AD) were not available (Martin, 2008) . Of note, most of the above clinical trials have involved agents Neurobiology of Disease 38 (2010) 482-491 
